Get started
Author

Nathan Fowler

Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial
2026 · John P. Leonard, Marek Trněný, et al. · Journal of Clinical Oncology · 3
Dual Immunotherapy in Aggressive Lymphoma (DIAL) study, a randomized phase 2 trial of Varlilumab in combination with Nivolumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
2026 · Rafael Hennemann Sassi, Susan Geyer, et al. · Research Square
PDF
Discovery and Characterization of Four Novel Vibrio coralliilyticus Phages Support the Proposal of Two New Genera
2026 · Jacob A. Albee, Nathan Fowler, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Structure of a key adhesin-exopolysaccharide interaction provides insights into matrix assembly in Vibrio cholerae biofilms
2026 · Alexander J. Hinbest, Hyerim Bianca Nam, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Malignant B-cell States Orchestrate Spatially Organized Immune Ecosystems in B-cell Lymphomas
2026 · Patrizia Mondello, Alisa Sadekova, et al. · Research Square
Conformational dynamics of exopolysaccharides underlie biofilm matrix mechanics in Vibrio cholerae
2026 · Kee-Myoung Nam, Nathan Fowler, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Erratum: Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial
2026 · John P. Leonard, Marek Trněný, et al. · Journal of Clinical Oncology
Ascension Island Seabird Monitoring Manual
2012 · Bolton, Mark, Fisher, Ian, et al. · University of Birmingham Research Portal (University of Birmingham)
Works count: 8
Citation count: 3
H-index: 1
I10-index:
Year
Topic
Type